AOD-9604

Origin and Structure

AOD-9604 ("Anti-Obesity Drug 9604") is a 16-amino-acid fragment corresponding to residues 177–191 of the human growth hormone (hGH) C-terminus, with an additional N-terminal tyrosine added for synthetic stability. It was developed in the 1990s at Monash University by Frank Ng and subsequently licensed to the Australian biotech Metabolic Pharmaceuticals. The design rationale was elegant on paper: isolate the lipolytic signaling activity of hGH's C-terminus while discarding the 191-residue full-length hormone's growth-promoting and insulin-antagonistic effects.

Proposed Mechanism

Preclinical work in Metabolic Pharmaceuticals' rodent models suggested that AOD-9604:

• Stimulated lipolysis in adipose tissue, mobilizing fatty acids for oxidation.
• Inhibited lipogenesis, reducing new fat storage.
• Did not bind the GH receptor and produced no measurable IGF-1 elevation, in contrast to full-length hGH or GH secretagogues.

The proposed receptor target is the beta-3 adrenergic receptor on adipocytes, though the mechanistic literature never fully resolved how a small peptide fragment produces that effect. Much of the early enthusiasm rested on the branding that AOD-9604 was "the fat-loss fragment of growth hormone" — a claim that turned out to be harder to validate in humans than in mice.

Clinical Evidence — What the Phase 2 Data Actually Showed

AOD-9604 is one of the rare research peptides with human Phase 2 data — and the result is the single most important fact for anyone evaluating it. A 12-week placebo-controlled trial in obese adults published by Metabolic Pharmaceuticals in 2007 reported weight loss in the AOD-9604 arm that was not statistically significantly different from placebo on the primary endpoint. Some secondary analyses favored the drug at specific doses, but the pre-specified primary analysis did not support the lipolytic thesis. A longer 24-week follow-on study was reportedly terminated early without positive readout.

Metabolic Pharmaceuticals subsequently pivoted AOD-9604 away from obesity entirely, toward osteoarthritis and cartilage-repair applications, where a small body of preclinical work suggested chondrocyte-related effects. Those programs have not advanced to convincing human efficacy data.

Regulatory Status and Marketing Claims

AOD-9604 has never been approved by the FDA for any indication. It holds GRAS ("Generally Recognized as Safe") status in the United States for use as a dietary ingredient — a regulatory classification that says nothing about efficacy. In Australia, the Therapeutic Goods Administration (TGA) has issued cautions about unapproved cosmetic and injectable preparations marketed around AOD-9604. The FDA placed AOD-9604 on the same Category 2 bulk drug substance list as BPC-157 in September 2023, prohibiting its compounding by Section 503A or 503B pharmacies.

Despite this, AOD-9604 is widely marketed by wellness and compounding clinics as a "fat loss peptide." The gap between that marketing and the actual clinical record is wide, and prospective users should weigh the two explicitly.

Safety

Tolerability data from the Phase 2 program was reassuring — AOD-9604 produced no meaningful changes in IGF-1, glucose, insulin, or standard safety labs, and adverse events were generally mild. The safety record is essentially "well tolerated but not effective at the doses studied," which is a very different conclusion than "safe and effective."

The Bottom Line

AOD-9604 is the clearest example in this library of a peptide whose marketing narrative has outlived its clinical evidence. The Phase 2 primary-endpoint miss in obesity is the single most important data point, and it rarely appears in the promotional materials that surround the compound. For practical fat-loss pharmacotherapy with actual human evidence, the relevant compounds are GLP-1 class agents like semaglutide and tirzepatide, not HGH fragments.